Interaksi Busulfan

Busulfan (Myleran, Busulfex) memiliki 37 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 3 mayor, 4 moderat, 30 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (3)

  • Do not administer bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride concomitantly with busulfan unless the benefit outweighs the risk. (label Bismut subsitrat, metronidazol, dan tetrasiklin, Peringatan dan perhatian)

  • MetronidazolantibiotikMayor

    Busulfan : Increased busulfan serum concentrations; avoid concomitant use, monitor for plasma concentrations and adjust the busulfan dose accordingly. (label Metronidazol, Interaksi obat)

  • SiklofosfamidimunosupresanMayor

    Hepatic veno-occlusive disease, which may be life threatening, has been reported in patients receiving busulfan, usually in combination with cyclophosphamide or other chemotherapeutic agents prior to bone marrow transplantation. (label Busulfan, Peringatan)

Interaksi moderat (4)

  • Deferasirokssuplemen zat besiModerat

    Deferasirox increases exposure of busulfan. (label Deferasiroks, Interaksi obat)

  • IfosfamidModerat

    Hemorrhagic cystitis is dose‑dependent and the risk is increased with past or concomitant radiation of the bladder or busulfan treatment. (label Ifosfamid, Peringatan dan perhatian)

  • Itrakonazolantijamur azolModerat

    The concomitant systemic administration of itraconazole to patients receiving high-dose MYLERAN may result in reduced busulfan clearance (see CLINICAL PHARMACOLOGY). (label Busulfan, Interaksi obat)

  • TiotepaModerat

    Hepatic Veno-Occlusive Disease Hepatic veno-occlusive disease may occur in patients who have received high-dose TEPADINA in conjunction with busulfan and cyclophosphamide [ see Adverse Reactions (6.1) ]. (label Tiotepa, Peringatan dan perhatian)

Penyebutan minor (30)

  • Azelastin dan flutikasonantihistaminMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • BeklometasonkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • BetametasonkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • BudesonidkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • Budesonid dan formoterolkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • DeflazakortkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • DeksametasonkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • DesonidkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • FludrokortisonkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • FlunisolidkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • FluosinonidkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • FlutikasonkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • Flutikason dan salmeterolkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • HalobetasolkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • HidrokortisonkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • KlobetasolkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • Levotiroksinhormon tiroidMinor

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (label Busulfan, Peringatan)

  • Levotiroksin dan liotironinhormon tiroidMinor

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (label Busulfan, Peringatan)

  • Liotironinhormon tiroidMinor

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (label Busulfan, Peringatan)

  • MerkaptopurinantimetabolitMinor

    During the pregnancy that resulted in the malformed infant, the mother received x-ray therapy early in the first trimester, mercaptopurine until the third month, then busulfan until delivery. (label Busulfan, Peringatan)

  • MetilprednisolonkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • MometasonkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • Olopatadin dan mometasonantihistaminMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • PrednisolonkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • PrednisonkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • Propiltiourasilobat antitiroidMinor

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (label Busulfan, Peringatan)

  • SiklesonidkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • Teriparatidhormon tiroidMinor

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (label Busulfan, Peringatan)

  • Tiamazolobat antitiroidMinor

    Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (label Busulfan, Peringatan)

  • TriamsinolonkortikosteroidMinor

    The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

Periksa Busulfan terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.